SCHEMBL25192579

SCHEMBL25192579

CCOC(=O)c1nn(-c2ccc(Cl)nc2)cc1C=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.53
RAB9A P51151 9/20 0.53
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 6/20 0.49
SMN1; SMN2 Q16637 6/20 0.49
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
GLA P06280 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CHEK1 O14757 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25188556 0.87 KDM4E (0.43) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2185500 0.86 NPC1 (0.71) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL20142902 0.83 NPC1 (0.70) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL16837112 0.83 NOTUM (0.55) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL31018430 0.82 ALDH1A1 (0.41) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL25189563 0.82 NPC1 (0.46) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2187732 0.80 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL1805402 0.76 NPC1 (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL25190083 0.75 NPC1 (0.44) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL18039620 0.75 NPC1 (0.52) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034149-A1 DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS AC IMMUNE SA (CH) 2025-01-30 US disclosed
EP-4430045-A1 DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS AC Immune SA (CH) 2024-09-18 EP disclosed
WO-2023083998-A1 DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS AC IMMUNE SA (CH) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034149-A1 DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS SNCA, PARK7, SLC6A3 NPC1 1044/4885RAB9A 212/4885KDM4E 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.